Edwards Lifesciences (EW) Net Cash Flow (2009 - 2026)

Edwards Lifesciences has reported Net Cash Flow for 18 years, with the latest figure at $458.4 million in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 168.38% year-over-year to $458.4 million in Q2 2026; TTM through Jun 2026 was -$394.8 million, a 123.5% decrease from a year earlier, with the FY2025 full-year figure at -$74.5 million, down 103.98% from the prior year.
• Net Cash Flow was $458.4 million for Q2 2026 at Edwards Lifesciences, up from -$500.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $2.1 billion in Q3 2024, with the low at -$675.6 million in Q4 2024.
• Average Net Cash Flow over 5 years is $111.1 million, with a median of $130.8 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow jumped 827.79% in 2023, then plunged 564.44% in 2026.
• Over 5 years, Net Cash Flow stood at -$460.9 million in 2022, then surged by 43.05% to -$262.5 million in 2023, then slumped by 157.37% to -$675.6 million in 2024, then soared by 135.7% to $241.2 million in 2025, then surged by 90.05% to $458.4 million in 2026.
• The last three Net Cash Flow figures came in at $458.4 million (Q2 2026), -$500.2 million (Q1 2026), and $241.2 million (Q4 2025), per Business Quant data.